<DOC>
	<DOCNO>NCT00613093</DOCNO>
	<brief_summary>Objectives : To define role O6-Benzylguanine ( BG ) restore Temodar ( temozolomide ) sensitivity patient Temodar-resistant malignant glioma . To define toxicity combo therapy use Temodar + BG .</brief_summary>
	<brief_title>Ph . II Temozolomide + O6-BG Treatment Pts w Temozolomide-Resistant Malignant Glioma</brief_title>
	<detailed_description>2 separate stratum accrue independently : Stratum 1-patients Glioblastoma Multiforme ( GBM ) . Stratum 2-patients Anaplastic Glioma [ anaplastic astrocytoma ( AA ) , anaplastic oligodendroglioma ( AO ) , anaplastic mixed ( AA AO ) ] . BG 120mg/m2 administer intravenously 1 hour follow immediately 48-hour infusion 30mg/m2/24hrs . Temozolomide 472mg/m2 administer orally , fast state , within 60 minute end 1-hour administration BG infusion . Treatment cycle may repeat every 28 day follow dose Temodar previous cycle . Temodar well tolerate adult child common toxicity mild myelosuppression . Other , less likely , potential toxicity include nausea vomiting , constipation , headache , alopecia , rash , burn sensation skin , esophagitis , pain , diarrhea , lethargy , hepatotoxicity , anorexia , fatigue hyperglycemia . Hypersensitivity reaction yet note Temodar . As case many anti-cancer drug , Temodar may carcinogenic . BG toxicity include agitation , lethargy , nausea , vomit , rapid heart rate , elevate liver function , &amp; leukemia ; , BG single agent . Transient lymphopenia see BG single agent .</detailed_description>
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Glioma</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<mesh_term>O ( 6 ) -benzylguanine</mesh_term>
	<criteria>Patients recurrent/progressive Malignant Glioma ( MG ) . Stereotactic biopsy time recurrence/progression require radiationinduced necrosis suspect Patients MG resistant Temodar , define &gt; = 25 percent increase tumor growth contrast enhance MRI/CT within 8 week last dose Temodar Age &gt; = 18 year Evidence measurable enhance disease contrastenhanced MRI , unless medically contraindicate . Interval least 2 week prior surgical resection/ 4 week prior radiotherapy/chemotherapy , enrollment protocol unless unequivocal evidence tumor progression . However , patient treat chemotherapy agent VP16 would normally retreat short interval may treat usual starting time even less 4 week last prior dose chemotherapy Karnofsky performance score &gt; = 60 percent Hematocrit &gt; 29 percent , absolute neutrophil count ( ANC ) &gt; 1,500 cells/microliter , platelet &gt; 100,000 cells/microliter Serum creatinine &lt; 1.5 mg/dl , Blood Urea Nitrogen ( BUN ) &lt; 25 mg/dl , Serum Glutamic Oxaloacetic Transaminase ( SGOT ) &amp; bilirubin &lt; 1.5 x upper limit normal ( ULN ) For patient corticosteroid , must stable dose 1 week prior entry , clinically possible , dose escalated entry dose level Signed inform consent approve Institutional Review Board ( IRB ) prior patient entry If sexually active , patient take contraceptive measure duration treatment Exclusion criterion : Pregnancy Comedication may interfere study result</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>Temodar</keyword>
	<keyword>Temozolomide</keyword>
	<keyword>O6-BG</keyword>
	<keyword>O6-Benzylguanine</keyword>
	<keyword>NSC 637037</keyword>
	<keyword>Temodar-Resistant Malignant Glioma</keyword>
	<keyword>Brain tumor</keyword>
	<keyword>CNS tumor</keyword>
	<keyword>Cerebral glioblastoma</keyword>
	<keyword>Anaplastic astrocytomas</keyword>
	<keyword>Glioma</keyword>
</DOC>